Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Rare Diseases

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Ranibizumab

Angiogenesis Inhibitors

Growth Inhibitors

6 patients will receive 3 injections of Ranibizumab (2 mg) a month apart.

6 patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.

intravitreal injections of ranibizumab once a month, times 3.

Ranibizumab 2 mg

6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.

0.5 mg Ranibizumab

Peter E Liggett, MD

Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma

Genentech, Inc.

New England Retina Associates

Adverse event data are not available to be reported per group or according to severity because the PI left the institution and adverse event data in the required format is not available.

patients will receive 3 injections of Ranibizumab (2 mg) a month apart.

Ranibizumab 2 mg: intravitreal injections of ranibizumab once a month, times 3.

High Dose Ranibizumab

patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.

0.5 mg Ranibizumab: 6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.

Standard Dose Ranibizumab

Total

Age, Categorical

Sex: Female, Male

Leslie Hurst- study coordinator

vascular occlusion

retinal detachment

persistent sub retinal fluid (srf)

metastatic death

complications were only assessed in the high dose group

To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications.

Spots Global Cancer Trial Database for ranibizumab 2 mg